Table 5 Characteristics of patients with ABPA receiving omalizumab with and without AR.
All participants | With AR | Without AR | P | |
|---|---|---|---|---|
Baseline Data | ||||
Blood eosinophil count, cells/µL | 590 (270–840) | 510 (190–910) | 630 (580–930) | 0.40 |
Total serum IgE level, kU/L | 2627 ± 1904 | 2540 ± 2050 | 2846 ± 1736 | 1.00 |
Dose of corticosteroids, mg/d | 2.5 (0.6–12) | 2.5 (0.6–14) | 4.5 (0.6–11) | 0.89 |
ACT score | 17 ± 5 | 16 ± 6 | 18 ± 4 | 0.67 |
FVC %pre | 81 ± 13 | 80 ± 11 | 83 ± 15 | 0.48 |
FEV1%pre | 69 ± 15 | 68 ± 15 | 71 ± 15 | 0.78 |
Acute exacerbation rate | 2 (0.8–3.3) | 1.5 (0.8–3.0) | 3.5 (0.5–5.0) | 0.32 |
Hospitalization rate | 1 (0–1.3) | 0.5 (0–1.0) | 1.5 (0.3–4.3) | 0.20 |
After treatment | ||||
Blood eosinophil count, cells/µL | 180 (120–490) | 240 (110–600) | 106 (110–420) | 0.62 |
Total serum IgE level, kU/L | 1913 ± 1898 | 2384 ± 2040 | 737 ± 735 | 0.16 |
Dose of corticosteroids, mg/d | 0.6 (0.5–4.2) | 0 (0.5–4.2) | 0.8 (0.1–6.3) | 0.94 |
ACT score | 22 ± 3 | 21 ± 3 | 23 ± 1 | 0.67 |
FVC %pre | 86 ± 17 | 84 ± 15 | 89 ± 22 | 0.40 |
FEV1%pre | 76 ± 18 | 77 ± 18 | 74 ± 21 | 0.67 |
Acute exacerbation rate | 0 (0–1.0) | 0 (0–1.3) | 0 (0–0.8) | 0.51 |
Hospitalization rate | 0 (0–0) | 0 (0–0.3) | 0 (0–0) | 0.35 |